ArticleScientific reports2026
Integration of hierarchical clustering in hematologic biomarkers prediction for endocrine toxicity during immunotherapy in lung cancer patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune check-point inhibitors (ICIs) have outstandingly changed the treatment for lung cancer patients providing longer progression-free (PFS) and overall survival (OS). Immune-related adverse events (irAEs) counteract this success, and different biomarkers are broadly investigated to predict their appearance. Hematologic predictive biomarkers for irAEs are extensively studied to better prevent, monitor and treat irAEs. This is a retrospective exploratory-in-nature cohort study of lung cancer patients treated with ICIs in a tertiary level hospital in Romania, from 1 November 2017 until 1 August 2024. We evaluate 173 non-small cell lung cancer (NSCLC) patients treated with at least three cycles of ICIs and we investigate the association between Endocrine-irAEs and hematologic variables, such as neutrophil-to-lymphocyte ratio (NLR), absolute neutrophils, lymphocytes and eosinophils count. We also revise the literature and use an Artificial Intelligence (AI) technique to interpret our endpoints. We identify a statistically significant correspondence between NLR value before ICIs initiation and all-irAEs [odds ratio (OR) 0.877, 95% confidence interval (CI) 0.763-0.979, p = 0.036], but not for Endocrine-irAEs (OR 0.898, 95% CI 0.781-1.031, p = 0.081). While significant barriers for identifying the patients at risk of developing irAEs are still present, the implementation of truly relevant and useful biomarkers remains challenging. NLR might be a useful and easy to assess tool in real-life clinical settings, but more research is needed to validate its prediction value in Endocrine-irAEs onset.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.